Figure 5
Figure 5. Effects of oridonin on AE targets. (A) Semiquantitative RT-PCR analysis shows a down-regulation of Bcl-2, G-CSFR, and MPO in Kasumi-1 cells treated with oridonin. (B) Quantitative real-time RT-PCR analysis of expression of AE target genes. (C-D) Flow cytometry analysis shows a diminution in expression of G-CSFR (C) and MPO (D) on Kasumi-1 cells treated with oridonin. (E-F) Pharmacologic modulation of AE, HDAC1, and acetyl histone H3 on promoters of BCL-2, MPO, IL-3, and GM-CSF. ChIP assay was done in Kasumi-1 (E) and U937-A/E (F) cells treated with oridonin at indicated concentrations using anti-ETO, HDAC1, and acetyl histone H3 antibodies. Error bars represent SD of experiments.

Effects of oridonin on AE targets. (A) Semiquantitative RT-PCR analysis shows a down-regulation of Bcl-2, G-CSFR, and MPO in Kasumi-1 cells treated with oridonin. (B) Quantitative real-time RT-PCR analysis of expression of AE target genes. (C-D) Flow cytometry analysis shows a diminution in expression of G-CSFR (C) and MPO (D) on Kasumi-1 cells treated with oridonin. (E-F) Pharmacologic modulation of AE, HDAC1, and acetyl histone H3 on promoters of BCL-2, MPO, IL-3, and GM-CSF. ChIP assay was done in Kasumi-1 (E) and U937-A/E (F) cells treated with oridonin at indicated concentrations using anti-ETO, HDAC1, and acetyl histone H3 antibodies. Error bars represent SD of experiments.

Close Modal

or Create an Account

Close Modal
Close Modal